Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 11, 2003. The report focuses on corporate governance matters, specifically changes in directors' interests in ordinary shares and applications for new share listings, rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or performance metrics are included in this specific report.
Material Changes
- Share Transfers: On December 9, 2003, the GlaxoSmithKline Employee Trust transferred 31,940 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Acquisition: Director Mr. J D Coombe acquired 20 ordinary shares on December 9, 2003, via the ShareReward Plan at a price of £12.90 per share (10 shares via personal contribution and 10 via company matching).
- New Listings: An application was made to the UK Listing Authority and London Stock Exchange for block listings totaling 155,884 ordinary shares (25p each). This includes 77,942 shares under the Share Option Plan-Ordinary and 77,942 shares under the Share Option Plan-ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items. The document is limited to reporting specific share transactions and listing applications.
Investor Verification Points
- Verify the total number of shares issued under the ShareReward Plan and Share Option Plans to assess potential dilution.
- Confirm the current share price relative to the £12.90 transaction price mentioned for Director Coombe.
- Check subsequent filings to confirm the admission of the 155,884 new shares to the Official List.
- Review the full annual report (Form 20-F) for comprehensive financial data, as this 6-K contains no financial metrics.